PDS Biotechnology licenses nanotech platform to Merck KGaA
Merck KGaA obtained rights to use PDS Biotechnology's nanotechnology platform Versamune for two experimental cancer drugs. -More-
Original Article: PDS Biotechnology licenses nanotech platform to Merck KGaA
NEXT ARTICLE